SkyePharma and Mundipharma entered into licensing agreement for marketing and distribution rights to SkyePharma’s DepoCyte® (cytarabine) for treating lymphomatous meningitis. The deal could be worth up to US$17.2 M to SkyePharma in addition to royalties on product sales.